Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Hiltonol (poly ICLC) Clear all
Terminated Phase 1 Interventional

Autologous OC-L Vaccine and Ovarian Cancer

NCT02452775
View directory record Official record
Conditions
Primary Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
OC-L, Montanide, poly-ICLC (Hiltonol),
Biological · Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists

NCT02126579
View directory record Official record
Conditions
Melanoma, Metastatic Melanoma, Mucosal Melanoma
Interventions
Peptide Vaccine (LPV7) + Tetanus peptide, PolyICLC, Resiquimod, IFA
Biological · Other
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
2
States / cities
Houston, Texas • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Sep 28, 2026, 9:51 PM EDT
Active, not recruiting Phase 1 Interventional

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

NCT04117087
View directory record Official record
Conditions
Colorectal Cancer, Pancreatic Cancer
Interventions
KRAS peptide vaccine, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 26, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Terminated Phase 1Phase 2 Interventional

Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1

NCT03721679
View directory record Official record
Conditions
Solid Cancer
Interventions
Poly-ICLC combination treatment with aPD-1 (Nivolumab or Pembrolizumab) or aPD-L1 (Atezolizumab or Durvalumab) over 6 months
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
3
States / cities
Chevy Chase, Maryland • Easton, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 31, 2021 · Synced Sep 28, 2026, 9:51 PM EDT
Active, not recruiting Phase 1 Interventional

NeoVax Plus Ipilimumab in Renal Cell Carcinoma

NCT02950766
View directory record Official record
Conditions
Kidney Cancer
Interventions
NeoVax, Ipilimumab
Drug
Lead sponsor
Patrick Ott, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 2, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

DCVax Plus Poly ICLC in Healthy Volunteers

NCT01127464
View directory record Official record
Conditions
HIV-1 Infection, HIV Infection, Healthy Volunteers
Interventions
DCVax-001, Poly-ICLC, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 7, 2014 · Synced Sep 28, 2026, 9:51 PM EDT
Recruiting Phase 1 Interventional

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

NCT06529822
View directory record Official record
Conditions
Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
Interventions
Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera or Altera testing
Biological · Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
3
States / cities
Orlando, Florida • St Louis, Missouri • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Not yet recruiting Phase 1 Interventional

A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

NCT07430202
View directory record Official record
Conditions
Liver Cancer (Fibrolamellar Hepatocellular Cancer (FLC))
Interventions
DNAJB1-PRKACA Peptide Vaccine, DRP-104, Nivolumab, Ipilimumab
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
12 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer

NCT00374049
View directory record Official record
Conditions
Prostate Cancer
Interventions
MUC_1
Drug
Lead sponsor
Olivera Finn
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 2 Interventional

Dendritic Cell Vaccine for Patients With Brain Tumors

NCT01204684
View directory record Official record
Conditions
Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
Interventions
autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 27, 2024 · Synced Sep 28, 2026, 9:51 PM EDT
Active, not recruiting Phase 1 Interventional

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors

NCT04616248
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8, Unresectable Breast Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Soft Tissue Sarcoma, Bone Sarcoma, Sarcoma,Soft Tissue, Sarcoma of Bone, Basal Cell Carcinoma
Interventions
Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy, Recombinant Flt3 Ligand, Pembrolizumab, Tocilizumab
Biological · Drug · Radiation
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Atezolizumab Given in Combination With a Personalized Vaccine in Patients With Urothelial Cancer

NCT03359239
View directory record Official record
Conditions
Urothelial/Bladder Cancer, Nos
Interventions
Atezolizumab, PGV001, Poly ICLC, Normal saline
Drug · Biological
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

NCT01834248
View directory record Official record
Conditions
Acute Myeloid Leukemia, Alkylating Agent-Related Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Refractory Anemia With Excess Blasts in Transformation
Interventions
DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis, Poly ICLC
Biological · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Safety and Immunogenicity of Personalized Genomic Vaccine to Treat Malignancies

NCT02721043
View directory record Official record
Conditions
Solid Tumors
Interventions
Peptides, Poly-ICLC, Lenalidomide
Biological · Drug
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2021 · Synced Sep 28, 2026, 9:51 PM EDT
Active, not recruiting Phase 1 Interventional

The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting.

NCT05010200
View directory record Official record
Conditions
Prostate Cancer
Interventions
PGV-001, Poly-ICLC, CDX-301
Biological
Lead sponsor
Ashutosh Kumar Tewari
Other
Eligibility
18 Years and older · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme

NCT02078648
View directory record Official record
Conditions
Adult Brain Glioblastoma, Glioblastoma Multiforme
Interventions
SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose), Bevacizumab, SL-701 + GM-CSF, Imiquimod
Drug
Lead sponsor
Stemline Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Early Phase 1 Interventional

Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas

NCT00795457
View directory record Official record
Conditions
Astrocytoma, Oligo-Astrocytoma, Glioma
Interventions
GAA/TT-peptide vaccine and poly-ICLC
Biological
Lead sponsor
Ian F. Pollack, M.D.
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Winston-Salem, North Carolina • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Sep 28, 2026, 9:51 PM EDT
Terminated Phase 1 Interventional

Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma

NCT00880867
View directory record Official record
Conditions
B Cell Lymphoma, T Cell Lymphoma
Interventions
Poly-ICLC
Drug
Lead sponsor
Nevada Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 19, 2011 · Synced Sep 28, 2026, 9:51 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs

NCT02332889
View directory record Official record
Conditions
Gliomas, Medulloblastoma, Neuroectodermal Tumors, Primitive
Interventions
Vaccine (autologous dendritic cells), Decitabine and Hiltonol
Biological · Drug
Lead sponsor
University of Louisville
Other
Eligibility
2 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 3, 2018 · Synced Sep 28, 2026, 9:51 PM EDT
Recruiting Phase 1 Interventional

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer

NCT05098210
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Cutaneous Melanoma, Locally Advanced Mucosal Melanoma, Metastatic Acral Melanoma, Metastatic Conjunctival Melanoma, Metastatic Cutaneous Melanoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Mucosal Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma, Recurrent HER2-Negative Breast Carcinoma, Recurrent Hormone Receptor-Positive Breast Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Recurrent Mucosal Melanoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Unresectable Acral Melanoma, Unresectable Cutaneous Melanoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Mucosal Melanoma
Interventions
Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Positron Emission Tomography, Ruxolitinib
Biological · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Withdrawn Phase 1 Interventional

Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

NCT05457959
View directory record Official record
Conditions
Diffuse Hemispheric Glioma, H3 G34-Mutant
Interventions
Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis, Nivolumab, Placebo Administration, Poly ICLC, Resection
Biological · Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
13 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced Sep 28, 2026, 9:51 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

NCT02134925
View directory record Official record
Conditions
Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia, Colorectal Tubulovillous Adenoma
Interventions
Laboratory Biomarker Analysis, MUC1 Peptide-Poly-ICLC Vaccine, Quality-of-Life Assessment, Saline
Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
40 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Rochester, Minnesota • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 28, 2026, 9:51 PM EDT
Active, not recruiting Phase 1 Interventional

NeoVax With Nivolumab in Patients With Ovarian Cancer

NCT04024878
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Nivolumab, NeoVax, Core Needle Biopsy
Drug · Biological · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 28, 2026, 9:51 PM EDT
Completed Phase 1 Interventional

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

NCT01842139
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
basiliximab, WT1 126-134 peptide vaccine, Montanide ISA 51 VG, poly ICLC, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 85 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 8, 2018 · Synced Sep 28, 2026, 9:51 PM EDT